UNIVERSAL CHIMERIC ANTIGEN EXPRESSING IMMUNE CELLS FOR TARGETING OF DIVERSE MULTIPLE ANTIGENS AND METHOD OF MANUFACTURING THE SAME AND USE OF THE SAME FOR TREATMENT OF CANCER, INFECTIONS AND AUTOIMMUNE DISORDERS

1 . A nucleic acid encoding a universal chimeric antigen receptor, wherein the receptor comprises three domains, wherein:

the first domain is a tag-binding domain,

the second domain is an extracellular hinge and a transmembrane domain, and

the third domain is a signal transduction domain,

wherein the tag-binding domain binds to a tag derived from any human nuclear protein.

2 . The nucleic acid according to claim 1 , wherein the tag is a short linear epitope from human nuclear La protein (E5B9), wherein the E5B9 comprises an amino acid sequence according to SEQ ID NO: 14.

3 . The nucleic acid according to claim 1 , wherein the tag-binding domain is an antibody or an antigen-binding fragment thereof, wherein the tag-binding domain constitutes an anti-La epitope scFv, preferably an anti-La epitope scFv according to SEQ ID NO: 3 and SEQ ID NO: 4.

4 . The nucleic acid according to claim 1 , wherein the hinge and transmembrane region is selected from hinge and transmembrane regions of human CD28 molecule, CD8a chain, NK cell receptors, preferably natural killer group NKG2D, or parts of a constant region of an antibody as well as combinations of different hinge and transmembrane domains thereof.

5 . The nucleic acid according to claim 1 , wherein the signal transduction domain is selected from cytoplasmic regions of CD28, CD137 (41BB), CD134 (OX40), DAP10 and CD27, programmed cell death-1 (PD-1), cytotoxic T-lymphocyte antigen 4 (CTLA-4), CD3, DAP12 and T cell activation inducing Fc receptors.

6 . The nucleic acid according to claim 1 , wherein the receptor further comprises a fourth domain which is a short peptide linker in an extracellular portion of the receptor.

7 . The nucleic acid according to claim 1 , wherein the nucleic acid comprises a nucleotide sequence according to SEQ ID NO: 1.

8 . A target module comprising a binding moiety specific for a certain human cell surface protein or protein complex, and a tag, wherein the tag is derived from a human nuclear La protein.

9 . The target module according to any of claim 8 , wherein the binding moiety comprises an antibody or antigen-binding fragment thereof that binds to CD2, CD3, CD4, CD8, CD10, CD19, CD20, CD22, CD23, CD33, CD38, CD44, CD52, CD99, CD123, CD274, TIM-3, members of the epidermal growth factor receptor family and mutants thereof, members of the ephrin receptor family, prostate specific antigens PSCA or PSMA, embryonic antigens, members of the vascular endothelia growth factor family, epithelia cell adhesion molecule EpCAM, alphafetoprotein (AFP), members of the mucin protein family, follicle stimulating hormone receptor, human high molecular weight-melanoma-associated antigen, folate binding protein (FBP), a-Folate receptor, ligands of the NKG2D receptor, members of the epithelia glycoprotein family, diasialogangliosides, members of the carbonic anhydrase family, members of the carbohydrate antigen family, members of the Rho family of GTPases, members of the high mobility group proteins and mutants thereof and wherein the binding moiety comprises alpha and beta chains or gamma and delta chains of a T cell receptor or fragments thereof, including auto-reactive T cell receptor-derived receptors, wherein such T cell receptor-derived binding moieties recognize and bind to peptides presented by human leukocyte antigen class I and II protein complexes.

10 . The target module according to claim 8 , wherein the binding moiety comprises a ligand to proteins and protein complexes which binds to cytokine receptors, ligands of NKG2D receptor or ligands to EGFR family members.

11 . The target module according to claim 8 , wherein the binding moiety comprises bi- or multispecific antigen specificities include binding to PSCA and PSMA antigen, CD19 and CD20 antigen, CD19, CD20, and CD22 antigen, CD33 and CD123 antigen, CD33 and CD99, CD33 and TIM-3, erb-1 and -2, or PSCA and erb-2.

12 . The target module according to claim 8 , wherein the binding moiety comprises an antibody or antigen-binding fragment thereof that binds to the La/SSB antigen, wherein the La/SSB antigen comprises an amino acid sequence according to SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31 or SEQ ID NO: 32.

13 . A nucleic acid encoding a target module according to claim 8 , wherein the nucleic acid comprises a nucleotide sequence according to SEQ ID NO: 10, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 23 or SEQ ID NO: 26.

14 . A cell or vector comprising a nucleic acid according to claim 1 .

15 . The cell according to claim 14 , wherein the cell is selected from the group of immune cells including a T cell, a Natural Killer cell, a cytotoxic T lymphocyte, and a regulatory T cell.

16 . A kit comprising:

a vector according to claim 14 and

a target module comprising a binding moiety specific for a certain human cell surface protein or protein complex, and a tag, wherein the tag is derived from any human nuclear protein, preferably from a human nuclear La protein and/or a vector encoding a nucleic acid comprising a nucleotide sequence according to SEQ ID NO:10, SEQ ID NO:17, SEQ ID NO:20, SEQ ID NO:23, or SEQ ID NO:26.

17 . A formulation comprising a cell according to claim 14 and/or a target module for administration to a subject, wherein the target module comprises a binding moiety specific for a certain human cell surface protein or protein complex, and a tag, wherein the tag is derived from a human nuclear La protein.

18 . Use of a cell according to claim 14 and a target module for stimulating a universal chimeric antigen receptor mediated immune response in a mammal, wherein said target module comprises a binding moiety specific for a certain human cell surface protein or protein complex, and a tag, wherein the tag is derived from a human nuclear La protein.